Literature DB >> 28138585

Letter in response to "Our HER2 is same as yours".

Satoshi Matsusaka1, Kazuhiro Yoshida2.   

Abstract

Entities:  

Year:  2016        PMID： 28138585      PMCID： PMC5244624          DOI： 10.21037/tgh.2016.03.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  10 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

Authors:  M Cuello; S A Ettenberg; A S Clark; M M Keane; R H Posner; M M Nau; P A Dennis; S Lipkowitz
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

3.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

Authors:  Y Yonemura; I Ninomiya; A Yamaguchi; S Fushida; H Kimura; S Ohoyama; I Miyazaki; Y Endou; M Tanaka; T Sasaki
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.

Authors:  A Ooi; M Kobayashi; M Mai; I Nakanishi
Journal:  Lab Invest       Date:  1998-03       Impact factor: 5.662

Review 6.  Genetic testing by cancer site: stomach.

Authors:  Nicki Chun; James M Ford
Journal:  Cancer J       Date:  2012 Jul-Aug       Impact factor: 3.360

7.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

Authors:  S Uchino; H Tsuda; K Maruyama; T Kinoshita; M Sasako; T Saito; M Kobayashi; S Hirohashi
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

Review 8.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

9.  Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.

Authors:  Satoshi Matsusaka; Takashi Kobunai; Noriko Yamamoto; Keisho Chin; Mariko Ogura; Gotaro Tanaka; Kazuaki Matsuoka; Yuichi Ishikawa; Nobuyuki Mizunuma; Toshiharu Yamaguchi
Journal:  Genes Cancer       Date:  2016-01

10.  Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).

Authors:  Satoshi Matsusaka; Atsushi Nashimoto; Kazuhiro Nishikawa; Akira Miki; Hiroto Miwa; Kazuya Yamaguchi; Takaki Yoshikawa; Atsushi Ochiai; Satoshi Morita; Takeshi Sano; Yasuhiro Kodera; Yoshihiro Kakeji; Junichi Sakamoto; Shigetoyo Saji; Kazuhiro Yoshida
Journal:  Gastric Cancer       Date:  2015-08-12       Impact factor: 7.370
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.